Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect
  • NCT06955741

Recruiting

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants - CN008-0026

Oppdatert: 16 mai, 2025   |   ClinicalTrials.gov

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.
Skriv ut denne siden CN008-0026
Last ned Veiledning for studiedeltakere

VELG SPRÅK

Vis detaljer

  • Phase 1

    Fase

  • Kjønn

  • 18-65

    Aldersgruppe

  • 1

    Sted(er)

  • Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: Arm A
Drug: BMS-986446 IV, Acetaminophen, Loratadine
Experimental: Arm B
Drug: BMS-986446 SC, Acetaminophen, Loratadine

Nøkkelkriterier for kvalifikasjon

Inclusion Criteria: - Participants must have a Body Mass Index (BMI) of 18.0 to 30.0 kg/m2. - Participants must be healthy as determined by medical history, physical examination, neurological examination, vital signs, 12-lead ECG, C-SSRS, and clinical laboratory evaluations. Exclusion Criteria: - Participants must not have clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis. - Participants must not have prior exposure to BMS-986446 (PRX005). - Other protocol-defined Inclusion/Exclusion criteria apply.

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046